IP Library Granted Patent US 9,442,085
Granted Patent B2
US 9,442,085 · App. 14/715,218 · Granted Sep 13, 2016

Method for analysis using X-ray fluorescence

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,442,085
App. No.
14/715,218
Granted
Sep 13, 2016
Kind
B2
Abstract

The present invention is a method to quantify biomarkers. The method uses an X-ray fluorescence spectrometer to perform an X-ray fluorescence analysis on the sample to obtain spectral features derived from the biomarker; and quantifying the X-ray fluorescence signal of the biomarker.

Claims (23)

1. A method to quantify biomarkers, comprising providing a sample comprising a biomarker, the biomarker comprising one or more chemicals that are related to a physiological condition; fractionating the sample to provide sample fractions; using an X-ray fluorescence spectrometer comprising an X-ray excitation source to perform an X-ray fluorescence analysis on a sample fraction to obtain spectral features derived from the biomarker; and quantifying the X-ray fluorescence signal of the biomarker; wherein the X-ray fluorescence spectrometer irradiates the sample fraction with polychromatic X-rays, and the X-ray fluorescence analysis comprises multiple X-ray fluorescence analyses obtained wherein the sample fraction is disposed at two or more different angles relative to the excitation source.

2. The method of claim 1 , further comprising preparing the sample for X-ray fluorescence by exposing the sample to a solution.

3. The method of claim 1 , further comprising homogenizing the sample prior to fractionating the sample.

4. The method of claim 1 , wherein fractionating the sample is performed using a technique selected from the group of techniques consisting of centrifugation, mechanical separation, chemical separation, enzymatic separation, condensation, chromatographic methods, gel electrophoresis, isoelectric focusing, 2D electrophoresis, precipitation, density gradient fractionation and immobilization of analytes to solid formats.

5. The method of claim 1 , wherein fractionating the sample comprises immobilization of analytes to solid formats wherein the solid formats are selected from the group consisting of beads, membranes, arrays, microarrays, spin plate, or well plates.

6. The method of claim 5 , wherein fractionation comprises immobilization of analytes utilizing well plates.

7. The method of claim 1 , wherein fractionation is performed by centrifugation.

8. The method of claim 1 , wherein the sample fraction is disposed on or in a sample holder, and the sample holder comprises at least one chemical element which is not present in the sample.

9. The method of claim 1 , further comprising the step of constructing a tomogram.

10. A method to diagnose abnormal conditions, comprising providing one or more clinical samples, the one or more clinical samples comprising a biomarker; fractionating the sample to provide sample fractions; using an X-ray fluorescence spectrometer comprising an X-ray excitation source to perform an X-ray fluorescence analysis on the sample fraction to obtain spectral features derived from at least one biomarker; and quantifying the X-ray fluorescence signal of the biomarker, wherein the X-ray fluorescence spectrometer irradiates the sample fraction with polychromatic X-rays, and the X-ray fluorescence analysis comprises multiple X-ray fluorescence analyses obtained wherein the sample fraction is disposed at two or more different angles relative to the excitation source.

11. The method of claim 10 , further comprising exposing the sample to a solution to prepare the sample for the X-ray fluorescence analysis.

12. The method of claim 10 , further comprising homogenizing the sample prior to fractionating the sample.

13. The method of claim 10 , wherein fractionating the sample is performed using a technique selected from the group of techniques consisting of centrifugation, mechanical separation, chemical separation, enzymatic separation, condensation, chromatographic methods, gel electrophoresis, isoelectric focusing, 2D electrophoresis, precipitation, density gradient fractionation and immobilization of analytes to solid formats.

14. The method of claim 10 , wherein fractionating the sample comprises immobilization of analytes to solid formats wherein the solid formats are selected from the group consisting of beads, membranes, arrays, microarrays, spin plate, or well plates.

15. The method of claim 14 , wherein fractionation comprises immobilization of analytes utilizing well plates.

16. The method of claim 10 , wherein fractionation is performed by centrifugation.

17. The method of claim 10 , wherein the sample fraction is disposed on or in a sample holder, and the sample holder comprises at least one chemical element which is not present in the sample.

18. The method of claim 10 , further comprising the step of obtaining data concerning the at least one of the one or more clinical samples using at least one other test.

19. The method of claim 18 , further comprising the step of comparing the spectral features derived from the biomarker to data obtained from the at least one other test.

20. The method of claim 10 , further comprising the step of constructing a tomogram.

21. A method to identify one or more abnormal portions of a sample, comprising fractionating a clinical sample to provide sample fractions; the clinical sample comprising normal and abnormal portions; disposing least one sample fraction in a sample holder; providing an X-ray fluorescence spectrometer, the X-ray fluorescence spectrometer comprising an X-ray excitation source; using the X-ray fluorescence spectrometer to perform an X-ray fluorescence analysis on the sample fraction to obtain spectral features derived from at least one biomarker; and using spectral features derived from the biomarker to determine whether at least one portion of the sample fraction is normal or abnormal, wherein the X-ray fluorescence is performed using excitation of the fractioned sample with polychromatic X-rays, and the X-ray fluorescence analysis comprises multiple X-ray fluorescence analyses obtained wherein the sample fraction is disposed at two or more different angles relative to the excitation source.

22. The method of claim 21 , further comprising preparing the sample for X-ray fluorescence by exposing the sample to a solution.

23. The method of claim 21 , further comprising the step of constructing a tomogram.

Assignments (13)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2020
From: ICAGEN, INC.; ICAGEN CORP.; XRPRO SCIENCES, INC.; CALDERA DISCOVERY, INC.
To: ADJACENT ACQUISITION CO., LLC
Reel/Frame 054069/0211 →
CHANGE OF NAME Recorded Oct 15, 2020
From: ADJACENT ACQUISITION CO., LLC
To: ICAGEN, LLC
Reel/Frame 054088/0578 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
Reel/Frame 052304/0304 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
Reel/Frame 052304/0712 →
TERMINATION Recorded Sep 11, 2018
From: GPB DEBT HOLDINGS II, LLC
To: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
Reel/Frame 047046/0311 →
TERMINATION Recorded Sep 11, 2018
From: GPB DEBT HOLDINGS II, LLC
To: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
Reel/Frame 047046/0214 →
SECURITY AGREEMENT Recorded Sep 5, 2018
From: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047016/0859 →
SECURITY AGREEMENT Recorded Sep 5, 2018
From: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047317/0860 →
SECURITY INTEREST Recorded May 15, 2017
From: ICAGEN, INC.; ICAGEN CORP.; ICAGEN-T, INC.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: GPB DEBT HOLDINGS II, LLC
Reel/Frame 042378/0935 →
SECURITY INTEREST Recorded May 15, 2017
From: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: GPB DEBT HOLDINGS II, LLC
Reel/Frame 042379/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2016
From: PETERSON, LORI J.; WARNER, BENJAMIN P.; ZAHLER, NATHAN H.; BHARTI, PRATIMA; HSIEH, CHANG-TAI; SOLOMON, EMILIA A.; MORTILLARO, CAMARON A.
To: CALDERA PHARMACEUTICALS, INC.
Reel/Frame 037613/0437 →
CHANGE OF NAME Recorded Jan 28, 2016
From: XRPRO SCIENCES, INC.
To: ICAGEN, INC.
Reel/Frame 037638/0543 →
CHANGE OF NAME Recorded Jan 28, 2016
From: CALDERA PHARMACEUTICALS. INC
To: XRPRO SCIENCES, INC.
Reel/Frame 037688/0745 →